President Announces Tariffs Aimed at Lowering Drug Costs

A new executive order proposes significant tariffs on imported pharmaceuticals, sparking debate about potential impacts on drug prices and investment.

United States President Donald Trump announced a strategy utilizing tariffs to reduce the cost of prescription medications. The initiative involves a forthcoming executive order that could impose tariffs up to 100% on certain patented drugs if pharmaceutical firms fail to secure agreements with the administration within the next several months. The executive order outlines a tiered system. Companies that establish “most favoured nation” pricing agreements and construct manufacturing facilities within the US would be exempt from tariffs, receiving a zero-percent rate. Those firms lacking such agreements but investing in US-based facilities would face a 20% tariff, escalating to 100% after four years. Senior administration officials stated that companies have up to 120 days and 180 days, respectively, to negotiate before the higher tariffs take effect. Despite this timeframe, the identities of specific companies and drugs at risk remain undisclosed, though the administration reports having already finalized 17 pricing deals with major drug manufacturers, with 13 having formally signed. The move, described by President Trump as necessary to safeguard national security against pharmaceutical imports, coincides with the first anniversary of his “Liberation Day” import tax policies, which were previously challenged and overturned by the Supreme Court. Pharmaceutical industry leaders voiced concerns, with PhRMA CEO Stephen J. Ubl arguing that increased taxes would elevate drug costs and potentially discourage billions in US investments. He emphasized the significant existing US footprint in biopharmaceutical production and highlighted the reliance on trusted US allies for drug sourcing. The administration has leveraged the tariff threat to negotiate agreements with companies like Pfizer, Eli Lilly, and Bristol Myers Squibb, securing commitments for lower drug prices. Simultaneously, the US has established trade frameworks with nations including the European Union, Japan, Korea, and Switzerland, implementing a 15% tariff on patented pharmaceuticals – a rate previously agreed upon for most goods.